Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dr. Dianne Murphy, M.D. Associate Director of Pediatrics September 12, 2000 Center for Drug Evaluation and Research Food and Drug Administration.

Published byDarrell Nelson Modified over 8 years ago

Similar presentations

Presentation on theme: "Dr. Dianne Murphy, M.D. Associate Director of Pediatrics September 12, 2000 Center for Drug Evaluation and Research Food and Drug Administration."— Presentation transcript:

1 Dr. Dianne Murphy, M.D. Associate Director of Pediatrics September 12, 2000 Center for Drug Evaluation and Research Food and Drug Administration

2

3 PEDIATRIC RULE UPDATE Division Waivers DeferralsBoth Cardiorenal21 Neuropharm37 1 Oncology41 Med. Imaging-1 Anesthetic22 GI57 3 Metabolic925 2 Anti-Infective32

4 PEDIATRIC RULE UPDATE Division Waivers DeferralsBoth Anti-Viral-9 Derm/Dental63 Anti-Inflam83 1 OTC9- Pulmonary-7 Reproductive43 Special Pathogen44 2

5  Cardiorenal26 / 24  Neuropharm25 / 18  Metabolic/Endo25 / 15  Anti-inflammatory22 / 36  Anti-viral20 / 20  Anesthetic/Abuse14 / 9  Derm/Dental13 / 7  Pulmonary12 / 9 PPSR’s / WR’s by Division

6  GI11 / 5  Special Pathogens10 / 6  Oncology 5 / 3  OTC 4 / 3  Anti-infective 3 / 2  Reproductive 1 / 0  Medical Imaging 0 / 0 TOTAL 191 / 157 PPSR’s / WR’s by Division

7 AAP Invitational Meeting: Studying Oncology Drugs for Pediatric Use February 2000 AAP Academic Researchers Advocacy Representative NCI PhRMA Pediatric Cancer Cooperative Groups FDA

Download ppt "Dr. Dianne Murphy, M.D. Associate Director of Pediatrics September 12, 2000 Center for Drug Evaluation and Research Food and Drug Administration."

Similar presentations

Parallel Session 9 Contemporary Challenges in Statistical Evaluation of Diagnostic Products Chairs:Gene Pennello (CDRH) Lakshmi Vishnuvajjala (CDRH) Stuart.

Parallel Session 9 Contemporary Challenges in Statistical Evaluation of Diagnostic Products Chairs:Gene Pennello (CDRH) Lakshmi Vishnuvajjala (CDRH) Stuart.
Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.

Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.
FDA Advisory Committees: A Unique Element of our Decision-Making Process Murray M. Lumpkin, M.D. Acting Deputy Commissioner International and Special Programs.

FDA Advisory Committees: A Unique Element of our Decision-Making Process Murray M. Lumpkin, M.D. Acting Deputy Commissioner International and Special Programs.
FDA Update on Laboratory Developed Tests Oversight Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division.

FDA Update on Laboratory Developed Tests Oversight Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division.
The National Coordinating Center for the Regional Genetic and Newborn Screening Service Collaboratives (NCC/RC System) ACTions Matter: A Candid Conversation.

The National Coordinating Center for the Regional Genetic and Newborn Screening Service Collaboratives (NCC/RC System) ACTions Matter: A Candid Conversation.
Oncologic Drugs Advisory Committee September 6, 2006 ODAC and the FDA Arms-Length or Arm-In-Arm? Abigail Alliance for Better Access to Developmental Drugs.

Oncologic Drugs Advisory Committee September 6, 2006 ODAC and the FDA Arms-Length or Arm-In-Arm? Abigail Alliance for Better Access to Developmental Drugs.
Research Protocol ACRIN 6678 Learning About PET/CT Scans: Can PET/CT scans provide helpful information for the treatment of non-small cell lung cancer?

Research Protocol ACRIN 6678 Learning About PET/CT Scans: Can PET/CT scans provide helpful information for the treatment of non-small cell lung cancer?
Consent for Research Study A Study for Women with Advanced Cervical Cancer: Learning whether an MRI scan with an investigative contrast agent (called.

Consent for Research Study A Study for Women with Advanced Cervical Cancer: Learning whether an MRI scan with an investigative contrast agent (called.
National Science Foundation Biotechnology Program.

National Science Foundation Biotechnology Program.
Importance of Pharmacogenetics in Oncology Richard Pazdur, MD. Director Office of Oncology Drug Products Center for Drug Evaluation and Research Food and.

Importance of Pharmacogenetics in Oncology Richard Pazdur, MD. Director Office of Oncology Drug Products Center for Drug Evaluation and Research Food and.
Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.

Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.
ACRIN 6671/GOG 0233 Consent for Research Study A study for Women with Advanced Cervical Cancer: Learning whether a PET/CT scan using an imaging agent called.

ACRIN 6671/GOG 0233 Consent for Research Study A study for Women with Advanced Cervical Cancer: Learning whether a PET/CT scan using an imaging agent called.
THE UNIVERSITY OF NEW MEXICO ▪ HEALTH SCIENCES CENTER Clinical and Translational Science Center (CTSC) 4/2009.

THE UNIVERSITY OF NEW MEXICO ▪ HEALTH SCIENCES CENTER Clinical and Translational Science Center (CTSC) 4/2009.
FMCSA Medical Programs Wellness Initiative MRB/MCSAC Meeting September 21-22, 2015 Pamela Perry RN, ACSM-CPT Nurse Consultant Medical Programs Division,

FMCSA Medical Programs Wellness Initiative MRB/MCSAC Meeting September 21-22, 2015 Pamela Perry RN, ACSM-CPT Nurse Consultant Medical Programs Division,
Update From FDA: Office of the Commissioner and Center for Drug Evaluation and Research Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.

Update From FDA: Office of the Commissioner and Center for Drug Evaluation and Research Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.
The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.

The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.
Program Coordinator Subcommittee Meeting UTHSCSA June 17, 2013 3:30 p.m. AAB 114.

Program Coordinator Subcommittee Meeting UTHSCSA June 17, :30 p.m. AAB 114.
1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.
You have 5 min…ask three people “What is the first thought that comes to mind when they hear the word drug ?”

You have 5 min…ask three people “What is the first thought that comes to mind when they hear the word drug ?”
Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.

Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.

Similar presentations

Ads by Google